UK Unveils Go-It-Alone Drug Approval System
Accelerated Reviews Part Of MHRA's Post-Brexit Plans
Special approval procedures for new drugs and biosimilars, more use of real-world data, a streamlined drug safety monitoring system, and a ‘patient-first culture.’ The MHRA has plenty of ideas in store for its post-Brexit life as a fully independent regulator from January next year.
You may also be interested in...
One Country, Two Regulatory Systems: Another Brexit Headache
The Northern Ireland Protocol brings added complexities that for medicines regulation in the UK, particularly in areas such as new drug approvals and batch release procedures.
New UK Drug Assessment Routes Among Latest Measures For No-Deal Brexit
The UK MHRA has updated its guidance on how it plans to regulate medicines and healthcare products if the UK leaves the EU without a deal. Among many other things, it includes the promise of free scientific advice for SMEs and details on how marketing applications for centrally authorized products will be converted into UK ones in the event of a hard Brexit.
WHO To Review Impact Of Mechanism For Tackling Substandard & Falsified Drugs
Recent incidents of illness and death caused by contaminated cough syrups show that there is a need to review the “member state mechanism” that is intended to coordinate efforts to tackle poor quality medical products, the World Health Organization says.